pembrolizumab,lenvatinib
eisai,merck
['hcc', 'leap002', 'lenva']
great discussion by dr katie kelley about the negative leap002 trial in #esmo22 ! we have come far in the standard tki treatment in hcc and given the os of 19mo of lenvatinib and 50% receiving 2nd line treatment - we need to change the nhs funding criteria 
An educator and an oncologist. 
Consultant MedOnc @NHSBartsHealth, YOC member @myESMO, co-chair of postgrad committee @AMEE_Online and many other hats